CYP19A1 and breast carcinoma: Aromatase inhibitors (AIs) lower estrogen levels by blocking the conversion of androgen to estrogen by the enzyme aromatase, and are used for treatment of post-menopausal women with ER+ breast cancer.3–5 TAM and AIs have been mainstay treatment options for many years and have improved outcomes in breast cancer patients.